Paloma Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-9,285
| Closed | -$8.94M | – | 1427 |
|
|
2024
Q1 | $8.94M | Buy |
9,285
+9,085
| +4,543% | +$8.64M | 0.47% | 42 |
|
|
2023
Q4 | $176K | Buy |
+200
| New | +$165K | 0.01% | 623 |
|
|
2023
Q3 | – | Sell |
-300
| Closed | -$216K | – | 890 |
|
|
2023
Q2 | $216K | Sell |
300
-200
| -40% | -$154K | 0.01% | 592 |
|
|
2023
Q1 | $411K | Buy |
+500
| New | +$377K | 0.01% | 523 |
|
|
2021
Q4 | – | Sell |
-14,800
| Closed | -$8.96M | – | 2068 |
|
|
2021
Q3 | $8.96M | Buy |
14,800
+2,700
| +22% | +$1.68M | 0.22% | 61 |
|
|
2021
Q2 | $6.76M | Buy |
12,100
+9,400
| +348% | +$4.76M | 0.12% | 146 |
|
|
2021
Q1 | $1.28M | Buy |
2,700
+2,200
| +440% | +$1.07M | 0.03% | 595 |
|
|
2020
Q4 | $242K | Buy |
+500
| New | +$270K | 0.01% | 1286 |
|
|
2020
Q1 | – | Sell |
-17,000
| Closed | -$6.38M | – | 1929 |
|
|
2019
Q4 | $6.38M | Buy |
17,000
+5,000
| +42% | +$1.68M | 0.1% | 176 |
|
|
2019
Q3 | $3.33M | Buy |
12,000
+3,900
| +48% | +$1.15M | 0.07% | 242 |
|
|
2019
Q2 | $2.54M | Buy |
8,100
+1,100
| +16% | +$366K | 0.04% | 332 |
|
|
2019
Q1 | $2.87M | Buy |
7,000
+3,700
| +112% | +$1.52M | 0.07% | 321 |
|
|
2018
Q4 | $1.23M | Sell |
3,300
-14,000
| -81% | -$5.12M | 0.04% | 396 |
|
|
2018
Q3 | $6.99M | Buy |
17,300
+14,100
| +441% | +$5.37M | 0.13% | 122 |
|
|
2018
Q2 | $1.1M | Sell |
3,200
-2,900
| -48% | -$907K | 0.02% | 689 |
|
|
2018
Q1 | $2.1M | Sell |
6,100
-5,700
| -48% | -$1.98M | 0.03% | 546 |
|
|
2017
Q4 | $4.44M | Sell |
11,800
-14,800
| -56% | -$5.99M | 0.06% | 313 |
|
|
2017
Q3 | $11.9M | Buy |
26,600
+16,000
| +151% | +$7.61M | 0.16% | 88 |
|
|
2017
Q2 | $5.21M | Sell |
10,600
-40,300
| -79% | -$17.6M | 0.06% | 307 |
|
|
2017
Q1 | $19.7M | Sell |
50,900
-50,400
| -50% | -$18.7M | 0.24% | 59 |
|
|
2016
Q4 | $37.2M | Buy |
101,300
+21,700
| +27% | +$8.25M | 0.36% | 27 |
|
|
2016
Q3 | $32M | Buy |
79,600
+77,600
| +3,880% | +$31.1M | 0.4% | 44 |
|
|
2016
Q2 | $698K | Hold |
2,000
| – | – | 0.01% | 1377 |
|
|
2016
Q1 | $721K | Sell |
2,000
-2,200
| -52% | -$907K | 0.01% | 1094 |
|
|
2015
Q4 | $2.28M | Sell |
4,200
-21,700
| -84% | -$11.8M | 0.06% | 319 |
|
|
2015
Q3 | $12M | Buy |
25,900
+5,800
| +29% | +$3.11M | 0.28% | 49 |
|
|
2015
Q2 | $10.3M | Buy |
+20,100
| New | +$9.81M | 0.2% | 105 |
|
Other funds holding REGN
Paloma Partners's REGN Position: Q2 2025 in Review
Paloma Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 352 shares — an estimated $223K sold.
Paloma Partners first reported a position in REGN in Q2 2013 and held it in 34 quarters. The position peaked at $43.5M in Q3 2015. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.
- Paloma Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Paloma Partners sold 352 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $223K.
- Paloma Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Paloma Partners's Regeneron Pharmaceuticals position peaked at $43.5M in Q3 2015.
- 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.
Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.